PRESS RELEASES		MORE >
6-27-2007	New prescription option available for osteopenia and osteoporosis Fosteum ‚™ (capsules), the first prescription product designed to safely address the underlying disease processes of osteopenia (OPe) and osteoporosis (OP), is now available nationwide from Primus Pharmaceuticals
6-27-2007	New Patent Protection For Limbrel Primus Pharmaceuticals, Inc. has announced the issuing of two new patents which provide single-source protection for Limbrel, the first prescription product developed to safely meet the nutritional requirements of patients with osteoarthritis (OA).
6-27-2007	Genistein Studied Now Available by Prescription in U.S. as Fosteum‚™ Annals of Internal Medicine has published the results of a two-year clinical study on the impact of genistein on bone loss.
NEWS & EVENTS		MORE >
2-01-2006	Medscape From WebMD Reports Limbrel, the first prescription product developed to safely meet the nutritional requirements of patients with osteoarthritis (OA), is being introduced nationally by Primus Pharmaceuticals, Inc.
9-19-2006	Chicago Tribune Interviews Leading Physicians Prescribing Limbrel in the Chicago Area Dr. Steven D. Levin, assistant professor of orthopedic surgery at the Northwestern University Feinberg School of Medicine and Chief Orthopedic Surgeon for sports medicine at Evanston Northwestern Healthcare Medical Group, has been prescribing Limbrel for about two years.
4-18-2007	Primus Pharmaceuticals and Carrington Labs Sign Long-Term Supply and Patent Licensing Agreements for Acemannan Hydrogel‚™ Primus Pharmaceuticals, Inc. announced it has signed multi-year supply and patent license agreements with Carrington Laboratories, Inc., of Dallas, Texas.
8-07-2007	Primus Pharmaceuticals: One To Watch - Until It Goes Public "While I am mainly dedicated to stock picks and the occasional pan, once in a while a private company catches my eye. I file it in my mental rolodex as one to watch when it goes public. Primus Pharmaceuticals is one of those cases..."
PRESS KITS		MORE >